(Q35692903)

9 August 2017

1 reference

title

Diagnosis and management of pituitary tumors: recent advances (English)

1 reference

9 August 2017

Cheryl A Pickett

1

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Primary Care: Clinics in Office Practice

9 August 2017

published in

1 reference

9 August 2017

volume

30

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

765-789

1 reference

Modern imaging of the pituitary

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

The pituitary "incidentaloma".

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935-1977.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Differential diagnosis of sellar masses

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Studies of prolactin secretion in human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Nursing behaviour, prolactin and postpartum amenorrhoea during prolonged lactation in American and !Kung mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Prolactin release during nursing and breast stimulation in postpartum and nonpostpartum subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Visual function in prolactinoma patients treated with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Vaginal bromocriptine in hyperprolactinemic patients and puerperal women

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Pregnancy and the hyperprolactinemic woman

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Evaluation of Acromegaly by Radioimmunoassay of Somatomedin-C

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Pituitary surgery for the management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Determinants of clinical outcome and survival in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Role of gamma knife radiosurgery in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Stereotactic radiosurgery for pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

1 reference

7 January 2021

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Clinical experience with Sandostatin LAR in patients with acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Octreotide LAR treatment throughout pregnancy in an acromegalic woman

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Successful pregnancy in a woman with acromegaly treated with octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Pituitary tumors: pathophysiology, clinical manifestations and management

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

1 reference

7 January 2021

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

The place of pegvisomant in the management of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Prevalence of the sleep apnea syndrome in acromegaly population.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Clinical review 110: Diagnosis and treatment of pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Pituitary tumours in the elderly: a 20 year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

New medical approaches in pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Surgical treatment of thyrotropin-secreting pituitary adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Thyrotropin secreting pituitary adenoma effectively treated with octreotide.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900094-0

7 January 2021

10.1016/S0095-4543(03)00094-0

Identifiers

DOI

1 reference

9 August 2017

1 reference